Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 10/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.36 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22390588 | 0.94 | RIPK1 (0.50) | RIPK1SCN9AHTR2AHTR2CHTR2B | |
| SCHEMBL29786587 | 0.81 | HTR2A (0.41) | SCN9AHTR2AHTR2CHTR2BPARP10 | |
| SCHEMBL20472323 | 0.81 | HTR2A (0.41) | SCN9AHTR2AHTR2CHTR2BPARP10 | |
| SCHEMBL22957638 | 0.80 | HTR2A (0.41) | RIPK1SCN9ASCN5AHTR2AHTR2C | |
| SCHEMBL22392368 | 0.79 | RIPK1 (0.43) | RIPK1SCN9AHTR2AHTR2CHTR2B | |
| SCHEMBL22392048 | 0.79 | RIPK1 (0.54) | RIPK1HTR2CPARP10PARP15 | |
| SCHEMBL24018791 | 0.78 | SCN9A (0.39) | RIPK1SCN9ASCN5AHTR2AHTR2C | |
| SCHEMBL22957828 | 0.78 | SCN9A (0.39) | RIPK1SCN9ASCN5AHTR2AHTR2C | |
| SCHEMBL24018827 | 0.77 | SCN9A (0.38) | RIPK1SCN9ASCN5AHTR2AHTR2C | |
| SCHEMBL22390570 | 0.76 | RIPK1 (0.43) | RIPK1HTR2AHTR2CHTR2BPARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200277296-A1 | AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277296-A1 | AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS | RIPK1, RIPK4, RIPK3 | RIPK1 1/4885SCN9A 2384/4885SCN5A 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.